ArticleCancer letters2009
Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.
Article in Cancer letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 71 citations in OpenAlex.
- Integrating machine-learning and nanotechnology to quantify pH-modulated oxaliplatin release.Scientific reports · 2025Article
- Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential.International journal of molecular sciences · 2025Review
- PACAP38 synergizes with irradiation to suppress the proliferation of multiple cancer cells via regulating SOX6/Wnt/β-catenin signaling.Frontiers in pharmacology · 2024Article
- Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges.Pharmaceutics · 2021Review
- BH3-mimetics: recent developments in cancer therapy.Journal of experimental & clinical cancer research : CR · 2021Review
- An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.Frontiers in endocrinology · 2019Review
- Strategies to improve micelle stability for drug delivery.Nano research · 2018Article
- Neuropeptide G Protein-Coupled Receptors as Oncotargets.Frontiers in endocrinology · 2018Review
- Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.Current opinion in endocrinology, diabetes, and obesity · 2016Review
- A new lipid-based nano formulation of vinorelbine.AAPS PharmSciTech · 2014Article
- 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.International journal of nanomedicine · 2014Article
- Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.Drug delivery and translational research · 2013Article
- A critical review of lipid-based nanoparticles for taxane delivery.Cancer letters · 2013Review
- Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Journal of nanomedicine & nanotechnology · 2013Article
- Key structure of brij for overcoming multidrug resistance in cancer.Biomacromolecules · 2013Article
- VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.Drug delivery and translational research · 2012Article
- Human pancreatic polypeptide in a phospholipid-based micellar formulation.Pharmaceutical research · 2012Article
- Impact of nanotechnology in cancer: emphasis on nanochemoprevention.International journal of nanomedicine · 2012Review
- Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects.Cancers · 2011Article
- Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates.ACS nano · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Multidrug resistance (MDR) of breast cancer cells still represents an unmet medical need in chemotherapy. To this end, the purpose of this study was to determine efficacy of paclitaxel loaded in sterically stabilized, biocompatible and biodegradable sterically stabilized mixed phospholipid nanomicelles (SSMM; size, approximately 15 nm) and actively targeted vasoactive intestinal peptide-grafted SSMM (SSMM-VIP) in circumventing P-gp-mediated paclitaxel resistance in BC19/3 cells, a human breast cancer cell line that expresses >10-fold higher P-gp than its parental sensitive cell line, MCF-7. We found that in drug sensitive MCF-7 cells, paclitaxel loaded in SSMM (P-SSMM) and SSMM-VIP (P-SSMM-VIP) significantly inhibited cell growth in dose-dependent fashion (p<0.05). Both formulations were approximately 7-fold more potent than paclitaxel dissolved in DMSO (P-DMSO). Efficacy of P-SSMM and P-SSMM-VIP was similar (p>0.5). By contrast, in drug resistant BC19/3 cells, P-SSMM-VIP was significantly more effective than either P-SSMM or P-DMSO ( approximately 2- and 5-fold, respectively; p<0.05). Collectively, these data indicate that actively targeted paclitaxel-loaded SSMM-VIP overcomes multiple drug resistance of BC19/3 cells. We suggest this formulation should be further developed to treat MDR breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.